The carriers of IFNG +874 T/A allele A had fewer infections and use of inhaled corticosteroids and the carriers of TLR4 +896 A/G allele G were more likely to need tympanostomy than noncarriers.
There were no significant differences in allele frequency between the AD and control groups.
These results indicate that elements of regulatory pathways involving transcription factor Sp1 may be useful targets for therapeutic intervention to prevent or reverse AD.
This interaction leads to a reduction of c-Jun DNA-binding activity and prevents the protein from activating transcription of AP-1-dependent promoters.